I don't believe that there is a requirement for OTC companies to have their share price at $1.00. As a result, I believe this would only be an issue if the company tries to uplist to NASDAQ.
It is my understanding that a NASDAQ uplisting is on the "backburner." The company is currently trying to concentrate on R&D & marketing it's technology to potential customers as well as fighting off the neusence lawsuits, which are are a distraction to the company's effort.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.